(EMAILWIRE.COM, June 19, 2019 ) "Market Overview
Pancreatic cancer is the 12th most common cancer in the world. The estimated five-year prevalence of people living with pancreatic cancer is 4.1 per 100,000, globally. This cancer is almost always fatal and is the seventh most common cause of death from cancer. Pancreatic cancer is closely related to body fat and high BMI, thereby being more prevalent in the developed countries. A report by the Centers for Disease Control and Prevention (CDC) estimated that pancreatic cancer resulted in the death of about 330,000 people in 2012 in the United States, which was around 4% of all deaths in the country.

Request a sample of Pancreatic Cancer Therapeutics and Diagnostics Market report @ http://www.arcognizance.com/enquiry-sample/453896

Estimates of the American Cancer Society suggested that in the United States alone, nearly 53,070 new cases of pancreatic cancer were recorded in 2016 and 41,780 deaths in the country were attributed to the same. In Europe, nearly 104,000 new cases of pancreatic cancer were estimated to be diagnosed in 2012. The extensive threat of pancreatic cancer is a major opportunity for companies to capitalize on the market through the expansion of product portfolios and market penetration. The high patient pool and increasing trends of the same are expected to propel the growth of the market.

Scope of the Report
Pancreatic cancer occurs when there is an uncontrollable growth of cells in the pancreas. Pancreatic cancer is categorized as exocrine and endocrine, based on the cells affected by cancer. Exocrine cells in pancreas create pancreatic enzymes. When cancer manifests in these cells, it is referred to as exocrine pancreatic cancer. Endocrine cells are a small cluster of cells and also called ‘islets of Langerhans’. These cells create hormones, such as insulin and glucagon, releasing them into the blood flow. Cancer in these cells is called endocrine pancreatic cancer.

Key Market Trends
Targeted Therapy Segment is expected to exhibit fastest growth rate over the forecast period

Pancreatic cancer therapeutics is basically classified into chemotherapy, surgery, targeted therapy, and others. The targeted therapy segment is expected to witness the fastest growth rate over the forecast period owing to the higher efficacy, increasing rate of innovations, and speedy drug approvals. Targeted therapy can be referred to as the treatment with the use of drugs or other biochemical substances in order to identify and target specific cancerous cells with no or minimal harm to the healthy cells surrounding the cancer cell. For instance, Tyrosine kinase inhibitors (TKIs) are a type of targeted therapy drugs that block the activity of cell growth in the cancerous cells. Erlotinib is an example of TKI used in targeted therapy for the treatment of pancreatic cancer.

North America dominated the overall market and is expected to retain its dominance

North America dominated the pancreatic cancer therapeutics and diagnostics market. In the United States, the average lifetime risk of pancreatic cancer for both men and women is about 1 in 65 (1.5%). Pancreatic cancer accounts for about 3% of all cancers in the United States and about 7% of cancer deaths. The Pancreatic Cancer Action Network predicts pancreatic cancer to become the second leading cause of cancer-related deaths in the United States, by 2020. With promising drugs in the pipeline, the US pancreatic cancer therapeutics and diagnostics market is expected to witness lucrative growth during the forecast period. The high healthcare spending and state-of-the-art healthcare facilities in the United States are expected to promote the growth of the market, indirectly. The country is also a hub for high-end R&D activities, which are anticipated to have a positive impact on the novel product developments and clinical trials.

Access this report of Pancreatic Cancer Therapeutics and Diagnostics Market @ http://arcognizance.com/report/pancreatic-cancer-therapeutics-and-diagnostics-market-growth-trends-and-forecast-2019-2024

Competitive Landscape
The presence of major market players, such as Amgen, Eli Lilly, F. Hoffmann La-Roche, Novartis, and Pfizer, among others is intensifying the competition. The market players are adopting strategies, such as rising R&D investments, mergers, acquisitions, and product innovations in order to sustain the increasing market rivalry.

Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- Report customization as per the client's requirements
- 3 months of analyst support

Buy The Report @ http://www.arcognizance.com/purchase/453896

Major Point of TOC:

Chapter One: INTRODUCTION

Chapter Two: RESEARCH METHODOLOGY

Chapter Three: EXECUTIVE SUMMARY

Chapter Four: MARKET DYNAMICS

Chapter Five: MARKET SEGMENTATION

Chapter Six: COMPETITIVE LANDSCAPE

Chapter Seven: MARKET OPPORTUNITIES AND FUTURE TRENDS

Request a sample of Pancreatic Cancer Therapeutics and Diagnostics Market report @ http://www.arcognizance.com/enquiry-sample/453896

About Us:
www.arcognizance.com  is an initiation in this new era of “analysis @ thought.” We are on a mission to replace the conventional research programs and give way to the latest methods and information for the organizations. We have created this hub of analytical research papers where you can get an access to the latest and the best research papers coming out from some reliable and budding research houses. After the advent of “new analytics""based on the data collection facilities of big data, the face of ""business research facilities"" has changed drastically. With ARC our experts have created a bookshelf where you can check out the research reports that are an outcome of the progression of knowledge in various industry sectors. Alongside you can also check some research papers, market reports, and forecasts that are talking about the ""out of the box""developments in the market.

Contact US:
Name: Analytical research cognizance
Address: 100 Church Street,
8th floor, Manhattan,
New York 10007
Phone: +1 (646) 434-7969 +91 90967 44448
Email: enquiry@arcognizance.com 

Follows to Twitter : https://twitter.com/ARCognizance

Follows to Linkdin : https://www.linkedin.com/company/arcognizance"

Contact Information:
Analytical Research Cognizance
Avanti dengale
Tel: +91 90967 44448
Email us


----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results